Amgen – Is Amgen, Inc. (AMGN) a Good Buy in the Drug Manufacturers
Amgen, Inc. (AMGN) is around the top of the Drug Manufacturers – General industry according to InvestorsObserver. AMGN received an overall rating of 52, which means that it scores higher than 52 percent of all stocks. Amgen, Inc. also achieved a score of 87 in the Drug Manufacturers – General industry, putting it above 87 percent of Drug Manufacturers – General stocks. Drug Manufacturers – General is ranked 133 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What’s Happening With Amgen, Inc. Stock Today?
Amgen, Inc. (AMGN) stock is lower by -0.69% while the S&P 500 has risen 0.39% as of 3:06 PM on Thursday, Apr 8. AMGN is lower by -$1.72 from the previous closing price of $248.12 on volume of 831,718 shares. Over the past year the S&P 500 has gained 48.95% while AMGN has risen 12.41%. AMGN earned $12.31 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 20.01.
Click Here to get the full Stock Score Report on Amgen, Inc. (AMGN) Stock.